|14.46||+0.1800||+1.26%||Vol 159.45K||1Y Perf -47.09%|
|Oct 4th, 2023 16:00 DELAYED|
|- -||0.26 1.80%|
|Target Price||39.00||Analyst Rating||Strong Buy 1.00|
|Potential %||169.71||Finscreener Ranking||★★★★ 53.60|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★★★+ 54.27|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||★★★★ 58.11|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||1.46||Earnings Rating||Strong Buy|
|Market Cap||187.79M||Earnings Date||6th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||6th Nov 2023|
|Estimated EPS Next Report||0.40|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||97.22K|
|Avg. Monthly Volume||89.19K|
|Avg. Quarterly Volume||124.54K|
Eagle Pharmaceuticals Inc. (NASDAQ: EGRX) stock closed at 14.46 per share at the end of the most recent trading day (a 1.26% change compared to the prior day closing price) with a volume of 159.45K shares and market capitalization of 187.78M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 108 people. Eagle Pharmaceuticals Inc. CEO is Scott L. Tarriff.
The one-year performance of Eagle Pharmaceuticals Inc. stock is -47.09%, while year-to-date (YTD) performance is -50.53%. EGRX stock has a five-year performance of -77.81%. Its 52-week range is between 14.07 and 40.85, which gives EGRX stock a 52-week price range ratio of 1.46%
Eagle Pharmaceuticals Inc. currently has a PE ratio of 18.30, a price-to-book (PB) ratio of 1.71, a price-to-sale (PS) ratio of 1.56, a price to cashflow ratio of 18.70, a PEG ratio of -, a ROA of 7.05%, a ROC of 8.87% and a ROE of 10.95%. The company’s profit margin is 10.74%, its EBITDA margin is 19.90%, and its revenue ttm is $255.91 Million , which makes it $19.66 revenue per share.
Of the last four earnings reports from Eagle Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.40 for the next earnings report. Eagle Pharmaceuticals Inc.’s next earnings report date is 06th Nov 2023.
The consensus rating of Wall Street analysts for Eagle Pharmaceuticals Inc. is Strong Buy (1), with a target price of $39, which is +169.71% compared to the current price. The earnings rating for Eagle Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Eagle Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Eagle Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.28, ATR14 : 0.70, CCI20 : -181.24, Chaikin Money Flow : -0.03, MACD : -0.70, Money Flow Index : 18.91, ROC : -8.83, RSI : 33.94, STOCH (14,3) : 13.76, STOCH RSI : 0.21, UO : 44.44, Williams %R : -86.24), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Eagle Pharmaceuticals Inc. in the last 12-months were: Tarriff Scott (Sold 60 000 shares of value $1 230 356 )
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.